Market revenue in 2023 | USD 65.8 million |
Market revenue in 2030 | USD 122.7 million |
Growth rate | 9.3% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.68% in 2024. Horizon Databook has segmented the India in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
India is considered a lucrative market for in vivo CRO services across the Asia Pacific. This is due to the availability of experts, low operational cost, and recognition of intellectual property rights & international guidelines.
In addition, efforts by several regulatory bodies, such as the Directorate General of Foreign Trade, the Director Controller General of India, and the Department of Biotechnology in India, to create a conducive environment for in vivo research are expected to drive growth during the forecast period.
India's pharmaceutical and biotechnology industries are witnessing significant growth, with annual estimated rates of 12% and 20%, respectively. This growth can be attributed to factors, including the pursuit of new in-house drug development projects and collaborations with international companies.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account